

# REFERENCES

## References

**Abbott KC, Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Cruess DF, Peters TG.(2003)** Hepatitis C and renal transplantation in the era of modern immunosuppression. [J Am Soc Nephrol.](#) ;14(11):2908-18

**Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA.(2004)**, The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. [Am J Transplant.](#);4(12):2032-7.

**Abdallah MA, Hull C, Horn TD. (2005)** Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc. *Arch Dermatol.*; 141(1):85-7.

**Alter HJ.( 1992)** New kit on the block: Evaluation of second-generation assays for detection of antibody to the hepatitis C virus. *Hepatology*; 15(2):350-3.

**Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, et al(1992)** The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. [N Engl J Med.](#); 327(27):1899-905.

**Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S, Giannini C, Boni P, Sabattini E, Pileri S, Tura S, Bernardi M.(1998)** Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. *Ann Intern Med.*; 129(4):294-8.

**Anonymous. (1997).**Management of hepatitis C. [NIH Consens Statement.](#);15(3):1-41.

**Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. (2004)** Thyroid disorders in chronic hepatitis C.[Am J Med.](#); 117(1):10-3.

**Ayaz C, Celen MK, Yuce UN, Geyik MF.( 2008)** Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. *World J Gastroenterol.*; 14(2):255-9.

**Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M.( 2000)** Renal disease associated with hepatitis C infection after kidney and liver transplantation. *Transplantation*; 70(2):255-61.

**Baid S, Pascual M, Williams WW Jr, Tolkoff-Rubin N, Johnson SM, Collins B, Chung RT, Delmonico FL, Cosimi AB, Colvin RB(1999)** Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients.[J Am Soc Nephrol.](#);10(1):146-53.

**Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M. (2003)** Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy.[Am J Transplant.](#); 3(1):74-8.

**Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL.(1995)** A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. [Mod Pathol.](#) 1995 Apr;8(3):232-8.

- Barril G, Quiroga JA, Sanz P, Rodríguez-Salvanés F, Selgas R, Carreño V.(2004)** Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. [Aliment Pharmacol Ther.](#);20(1):37-44.
- Bedossa P, Poynard T(1996)** An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. [Hepatology.](#) ;24(2):289-93.
- Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. (2000).** Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation, *Hepatology*; 32 (1):87-90.
- Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G(2005),** The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology.*;65(6):807-11.
- Bräu N, Bini EJ, Stancic S, Finch DA, Aytaman A(2003)** Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C. [J Hepatol.](#); 38(6):871-2.
- Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Peters TG, Abbott KC.(2002),** Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation.[J Am Soc Nephrol.](#) ;13(12):2974-82.
- Bukh J, Miller RH, Purcell RH.( 1995)** Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes.*Semin Liver Dis.*;15(1):41-63.
- Cacoub P, Musset L, Amoura Z, Guilani P, Chabre H, Lunel F, Poynard T, Opolon P, Piette JC. (1997)** Anticardiolipin, anti-beta2-glycoprotein I, and antinucleosome antibodies in hepatitis C virus infection and mixed cryoglobulinemia.MultivircGroup.[J Rheumatol.](#); 24(11):2139-44.

**Campistol JM, Esforzado N, Martínez J, Roselló L, Veciana L, Modol J, Casellas J, Pons M, de Las Cuevas X, Piera J, Oliva JA, Costa J, Barrera JM, Bruguera M.(1999)** Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. [Nephrol Dial Transplant.](#) ;14(11):2704-9.

**Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Pérez JL, Guerrero L, González MT, Andres E, Gil-Vernet S, Casais LA.( 2001)**Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.[Am J Gastroenterol.](#); 96(4):1170-7.

**Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Del Vecchio S, Mazzilli C, Antonelli G, Bonomo L. (1997)** Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection.[Blood.](#); 90(10):3865-73.

**Castelnovo C, Sampietro M, De Vecchi A, Corbetta N, Cantù M, Orlandi A, Lunghi G, Ponticelli C.(1997)** Diffusion of HCV through peritoneal membrane in HCV positive patients treated with continuous ambulatory peritoneal dialysis. [Nephrol Dial Transplant.](#);12(5):978-80.

**Cattau EL Jr, Benjamin SB, Knuff TE, Castell DO. (1982)** The accuracy of the physical examination in the diagnosis of suspected ascites.[JAMA.](#) ;247(8):1164-6.

- Cooreman MP, Schoondermark-Van de Ven EM(1996)** Hepatitis C virus: Biological and clinical consequences of genetic heterogeneity.Scand J Gastroenterol Suppl.; 218:106-15.
- Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS.(2007)** Prevalence of chronic kidney disease in the United States. [JAMA](#). 298(17):2038-47.
- Cosio FG, Sedmak DD, Henry ML, Al Haddad C, Falkenhain ME, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM.(1996)** The high prevalence of severe early posttransplant renal allograft pathology in hepatitis C positive recipients. [Transplantation](#).; 62(8):1054-9.
- Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE.(2000)** The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med.;6(12):1375-9. Erratum in: Nat Med 2001 Feb; 7(2):255.
- Cruzado JM, Carrera M, Torras J, Grinyó JM.(2001)** Hepatitis C virus infection and de novo glomerular lesions in renal allografts. [Am J Transplant](#).;1(2):171-8.
- Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyó JM.,(2003)** Pretransplant Interferon Prevents Hepatitis C Virus-Associated Glomerulonephritis in Renal Allografts by HCV-RNA Clearance. American Journal of Transplantation. 3(3):357-360.
- Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR, Edelman R(1993)** Risk factors associated with a high seroprevalence of

hepatitis C virus infection in Egyptian blood donors. *Am J Trop Med Hyg.* ;49(4):440-7.

**David WS, Peine C, Schlesinger P, Smith SA. (1996)** Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C. [Muscle Nerve.](#);19(12):1596-602.

**Davis GL, Lau JY (1997)** Factors predictive of a beneficial response to therapy of hepatitis C. *Hepatology.*;26(3 Suppl 1):122S-127S.

**Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ.(2006)**Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. [J Hepatol.](#); 44(3):455-61.

**Donahue JG, Muñoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, Reitz BA, Nelson KE.( 1992)** The declining risk of post-transfusion hepatitis C virus infection. *N Engl J Med.* ;327(6):369-73.

**DuBois DB, Gretch D, dela Rosa C, Lee W, Fine J, Blagg CR, Corey L.(1994)** Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. [Am J Kidney Dis.](#) ;24(5):795-801.

**Eddy S, Wim R, Peter VE, Tanja R, Jan T, Werner VS.(1999 )**Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection. *Dig Dis Sci.*;44(1):186-9.

**Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ.(2007)** Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. [Proc Natl Acad Sci U S A.](#) ;104(20):8427-32.

**El-Serag HB, Hampel H, Yeh C, Rabeneck L. (2002)**Extrahepatic manifestations of hepatitis C among United States male veterans.[Hepatology](#).;36(6):1439-45.

**Erlinger, S, Benhamou, J., McIntyre, N, Benhamou, J, Rizzetto, M, Rodes, J (Eds),(1991).** Cirrhosis: Clinical aspects. In: Oxford Textbook of Clinical Hepatology University Press, Oxford 1991. p.380 .

**Fabrizi F, Bunnapradist S, Martin P,(2005).**chapter 11 Kidney Transplantation and Liver Disease in Handbook of Kidney Transplantation ,4th Edition,(DANOVITCH, GABRIEL M),P341.

**Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. ( 2004)** Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis.*Aliment Pharmacol Ther.*;20(11-12):1271-7.

**Fabrizi F, Poordad FF, Martin P.( 2002)** Hepatitis C infection and the patient with end-stage renal disease. *Hepatology.* ;36(1):3-10.

**Farrell GC, Bacon BR, Goldin RD(1998)** Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. [Hepatology](#).; 27(4):1121-7.

**Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A; Austrian Hepatitis Study Group.(2006)** Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection.*J Hepatol.*; 44(2):275-82.

**Fernández JL, Rendo P, del Pino N, Viola L.(1997)** A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. [J Viral Hepat.](#); 4(2):113-9.

**Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, Vazquez R, Ocete E, Olea N, Salmeron J.(1998)** Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. [Arch Intern Med.](#);158 (13):1445-8.

**Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ.(2005)** National surveillance of dialysis-associated diseases in the United States, 2002. [Semin Dial.](#) ;18(1):52-61.

**Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E, Lahm A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A.(2006)** A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. [Nat Med.](#); 12(2):190-7.

**Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P(2004)** Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. [Am J Gastroenterol.](#) ;99(5):873-7.

**Fortin, E(1998)** Neurovisual complications of interferon-alpha therapy. [Hepatology.](#) ;27(5):1441-2.

**Franciscus A ,(2007) HCSP • VERSION 2.3 • December 2008 (Online accessed 3 Jan 2009)**

URL:[www.hcvadvocate.org/hepatitis/factsheets\\_pdf/grade\\_stage\\_biopsy\\_2008.pdf](http://www.hcvadvocate.org/hepatitis/factsheets_pdf/grade_stage_biopsy_2008.pdf).

**Froio N, Nicastrì E, Comandini UV, Cherubini C, Felicioni R, Solmone M, Di Giulio S, Petrosillo N.(2003)** Contamination by hepatitis B and C viruses in the dialysis setting. [Am J Kidney Dis.](#); 42(3):546-50.

**Gallay BJ, Alpers CE, Davis CL, Schultz MF, Johnson RJ.(1995)** Glomerulonephritis in renal allografts associated with hepatitis C infection: a possible relationship with transplant glomerulopathy in two cases.[Am J Kidney Dis.](#) ;26(4):662-7.

**Garcia-Tsao G, (2007)** Chapter 157 Cirrhosis And Its Sequelae in Goldman: Cecil Medicine, 23rd ed. Copyright © [2007 Saunders, An Imprint of Elsevier](#).pp1141

**Garcia-Tsao G, (2007)** Chapter 157 Cirrhosis And Its Sequelae in Goldman: Cecil Medicine, 23rd ed. Copyright © [2007 Saunders, An Imprint of Elsevier](#).pp1142.

**Garcia-Valdescasas J, Bernal MC, Cerezo S, Garcia F, Pereira BJJ (1993)** .Strategies to reduce the transmission of HCV infection in hemodialysis (HD) units. (abstract),J Am Soc Nephrol 4:347.

**Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC.(2003)** L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. [Proc Natl Acad Sci U S A.](#); 100(8):4498-503.

**Glue P(1999)** clinical pharmacology of ribavirin.Semin Liver Dis.;19 Suppl 1:17-24

**González-Roncero F, Gentil MA, Valdivia MA, Algarra G, Pereira P, Toro J, Sayago M, Mateos J(2003)** Outcome of Kidney Transplant in Chronic Hepatitis C Virus Patients: Effect of Pretransplantation Interferon-Alpha2b Monotherapy Transplantation Proceedings, 35, 1745–1747.

**Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB(2008)** Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis.; 51(2):263-77.

**Gordon, E. W. August, (1998)** Utilization of Short-Stay Hospitals: Summary of Nonmedical Statistics: United States, 64 pp., [National Center for Health Statistics](#)(NCHS) Vital and Health Statistics Series 13, No. 14.

**Gretch DR.( 1997)** Diagnostic tests for hepatitis C. Hepatology.; 26(3 Suppl 1):43S-47S.

**Hadziyannis S, Karamanos B.( 1999)** Diabetes mellitus and chronic hepatitis C virus infection.Hepatology.;29(2):604-5.

**Halfon P, Levy M, San Marco M, Gerolami V, Khiri H, Bourliere M, Feryn JM, Gastaut JL, Pouget J, Cartouzou G.(1996)** Myasthenia gravis and hepatitis C virus infection.[J Viral Hepat.](#);3(6):329-32.

**Hammoud H, Haem J, Laurent B, Alamartine E, Diab N, Defilippis JP, Berthoux P, Berthoux F.(1996)** Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant. ;11 Suppl 4:54-5.

**Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, Ben Redjeb S, Izopet J.( 2006)** Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission.*J Med Virol.*;78(2):185-91.

**Hoofnagle JH, (2007)** Chapter 152 – Chronic Hepatitis in Goldman: Cecil Medicine, 23rd ed. Copyright © [2007 Saunders, An Imprint of Elsevier](#).pp1109.

**Hoofnagle JH, (2007)** Chapter 151 - Acute Viral Hepatitis in Goldman: Cecil Medicine, 23rd ed. Copyright © [2007 Saunders, An Imprint of Elsevier](#).pp1101.

**Hoofnagle JH, (2007)**Chapter 151 Acute Viral Hepatitis in Goldman: Cecil Medicine, 23rd ed. Copyright © [2007 Saunders, An Imprint of Elsevier](#).pp1102.

**Hoofnagle JH, (2007)**Chapter 152 – Chronic Hepatitis in Goldman: Cecil Medicine, 23rd ed. Copyright © [2007 Saunders, An Imprint of Elsevier](#).pp1113.

**Houglum K, Venkataramani A, Lyche K, Chojkier M.(1997)** A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. [Gastroenterology](#).;113(4):1069-73.

**Hu KQ, Tong MJ. (1999)**The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. [Hepatology](#).; 29(4):1311-6.

**Huraib S, Iqbal A, Tanimu D, Abdullah A (2001)** Sustained Virological and Histological Response with Pretransplant Interferon Therapy in Renal Transplant Patients with Chronic Viral Hepatitis C *Am J Nephrol* 2001;21:435-440.

**Huraib S, Tanimu D, Romeh SA, Quadri K, Al Ghamdi G, Iqbal A, Abdulla A. (1999)** Interferon-alpha in chronic hepatitis C infection in dialysis patients. [Am J Kidney Dis.](#);34(1):55-60.

**Idéo G, Bellobuono A, Tempini S, Mondazzi L, Airoidi A, Benetti G, Bissoli F, Cestari C, Colombo E, Del Poggio P, Fracassetti O, Lazzaroni S, Marelli A, Paris B, Prada A, Rainer E, Roffi L.(1999)** Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: A randomized, multicentre study. *Eur J Gastroenterol Hepatol.* ;11(11):1203-7.

**Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al.(1995)** Histological grading and staging of chronic hepatitis.[J Hepatol.](#);22(6):696-9.

**Jacobi C, Wenkel H, Jacobi A, Korn K, Cursiefen C, Kruse FE(2007)** Hepatitis C and ocular surface disease.*Am J Ophthalmol.*;144(5):705-711.

**Jacobson JM, Feinman L, Liebes L, Ostrow N, Koslowski V, Tobia A, Cabana BE, Lee D, Spritzler J, Prince AM.(2001)** Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. [Antimicrob Agents Chemother.](#) ;45(2):517-24.

**Jadoul M, Cornu C, van Ypersele de Strihou C.(1993)** Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. *Kidney Int.* ;44(6):1322-6.

**K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations (2006)** Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access (2006 Jul) *Am J Kidney Dis.* ;48 Suppl 1:S91-7.

**K/DOQI clinical practice guidelines for chronic kidney disease (2002):** evaluation, classification, and stratification [Am J Kidney Dis.](#) 39(2 Suppl 1):S1-266.

**Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L.( 2003)** Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. [Am J Kidney Dis.](#);42(1):184-92.

**Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L.( 2003)** Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. [J Am Soc Nephrol.](#) ;14(8):2092-8.

**Kaplan MM, DeLellis RA, Wolfe HJ.( 1997)** Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. [Ann Intern Med.](#) ;126(9):682-8.

**Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, Sasada Y, Shimizu E, Murohisa G, Koide S, Yoshimi T, Nakamura H, Ohno R.(1999)** Serum thrombopoietin levels in

patients with chronic hepatitis and liver cirrhosis. *Am J Gastroenterol.* ;94 (7):1918-22.

**KDIGO (2008)**, Clinical Practice Guidelines for the Prevention,Diagnosis, Evaluation,and Treatment of Hepatitis C in Chronic Kidney Disease, *Kidney International*,73 (Suppl 109),S20–S45

**Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S.( 2007)** Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. [Hepatology.](#) ;46(3):631-9.

**Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J(1981)** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology.* ;1(5):431-5.

**Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J.(1981).** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology.*;1(5):431-5.

**Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, Rush D, Cole E; Kidney Transplant Working Group of the Canadian Society of Transplantation.( 2005)** Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. [CMAJ.](#) 173(10):1181-4.

**Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ.( 1997)** The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. *Am J Kidney Dis.*;29(4):608-14.

**Kryczka, W, Brojer, E, Kowalska, A, Zarebska-Michaluk, D.(2001)** Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. *Med Sci Monit.* ;7 Suppl 1:221-5.

**Kuzushita N, Gregory SH, Monti NA, Carlson R, Gehring S, Wands JR.(2006)** Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. [Gastroenterology](#); 130(2):453-64.

**Kwon, YS, Choe, YH, Chin, HS(2001)** Development of glaucoma in the course of interferon alpha therapy for chronic hepatitis B. [Yonsei Med J.](#) ;42(1):134-6.

**Lake JR. (2003)**,The role of immunosuppression in recurrence of hepatitis C .  
*Liver Transpl*;9(11):S63-6

**Lau JY, Davis GL, Brunson ME, Qian KP, Lin HJ, Quan S, DiNello R, Polito AJ, Scornik JC.( 1993)** Hepatitis C virus infection in kidney transplant recipients. *Hepatology*.;18(5):1027-31.

**Lawitz EJ, Hepburn MJ, Casey TJ.( 2004)** A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. [Am J Gastroenterol.](#) ;99(12):2359-64.

**Lin CC, Yeh LT, Vitarella D, Hong Z.( 2003)** Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. [Antivir Chem Chemother.](#) ;14(3):145-52.

**Lindsay KL(1997)** Therapy of hepatitis C: overview. *Hepatology.* ;26(3 Suppl 1):71S-77S.

**Lodish, H, Baltimore, D, Berk, A, et al(1995).** Molecular cell biology. Scientific American Books, 3rd ed, Oxford Press, New York 1995. p.916.

**Lok AS, Gunaratnam NT.(1997)** Diagnosis of hepatitis C.[Hepatology](#).;26(3 Suppl 1):48S-56S.

**Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, Magee JC, Sung RS. (2008),**Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.[Transplantation](#). 15;85(11):1601-6

**Luciani G, Bossola M, Muscaritoli M, Panocchia N, Ferrante A, Nanni G, Piccioni E, Tazza L, Grillo RL, Rossi Fanelli F, Castagneto M. (2003)** Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. [J Nephrol](#).; 16(3):417-20.

**Maddrey WC.( 1999)** Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. [Semin Liver Dis](#). ;19 Suppl 1:67-75.

**Mahmoud IM, Elhabashi AF, Elsayy E, El-Husseini AA, Sheha GE, Sobh MA.( 2004)** The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. [Am J Kidney Dis](#). ;43(1):131-9.

**Mahmoud IM, Sobh MA, Amer GM, El-Chenawy FA, Gazareen SH, El-Sherif A, El-Sawy E, Ghoneim MA(1999)** A prospective study of

hepatitis C viremia in renal allograft recipients. *Am J Nephrol.* ;19(5):576-85.

**Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA.(2005)** Interferon Therapy in Hemodialysis Patients with Chronic Hepatitis C: Study of Tolerance,Efficacy and Post-Transplantation Course. *Nephron Clin Pract* ;100:c133–c139.

**Major ME, Feinstone SM (1997)** The molecular virology of hepatitis C *Hepatology.* ;25(6):1527-38.

**Maluf DG, Fisher RA, King AL, Gibney EM, Mas VR, Cotterell AH, Shiffman ML, Sterling RK, Behnke M, Posner MP.(2007)** Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival.*Transplantation.* 15;83(7):853-7.

**Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK(2001).** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial. *Lancet.* ;358(9286):958-65.

**Martin P, Fabrizi F.( 2008)** Hepatitis C virus and kidney disease. [J Hepatol.](#) ;49(4):613-24.

**Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C,Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. (1999),**Impact of hepatitis B and C virus on kidney transplantation outcome. [Hepatology.](#);29(1):257-63

**McGuire BM, Julian BA, Bynon JS Jr, Cook WJ, King SJ, Curtis JJ, Accortt NA, Eckhoff DE.(2006)** Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. [Ann Intern Med.](#);144(10):735-41.

**McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK.(1998)** Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.N Engl J Med.;339(21):1485-92.

**Merican I, Sherlock S, McIntyre N, Dusheiko GM. (1993)** Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. [Q J Med.](#);86(2):119-25.

**Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, Shintani AK, Walker CM, Kalams SA.(2004)** Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape.[J Exp Med.](#);200(3):307-19.

**Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH.(2003)** Hepatitis C and renal disease: An update.Am J Kidney Dis.;42(4):631-57.

**Mills PR, Vallance R, Birnie G, Quigley EM, Main AN, Morgan RJ, Russell RI, Watkinson G. (1981)**A prospective survey of radiological bone and joint changes in primary biliary cirrhosis. [Clin Radiol.](#) ;32(3):297-302.

**Monti G, Pioltelli P, Saccardo F, Campanini M, Candela M, Cavallero G, De Vita S, Ferri C, Mazzaro C, Migliaresi S, Ossi E, Pietrogrande M, Gabrielli A, Galli M, Invernizzi F. (2005)**Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias.[Arch Intern Med.](#) ;165(1):101-5.

**Morales JM, Campistol JM.( 2000 )** Transplantation in the patient with hepatitis C [J Am Soc Nephrol.](#);11(7):1343-53.

**Morales JM, Campistol JM, Andrés A, Dominguez-Gil B, Esforzado N, Muñoz MA, Bruguera M, Oppenheimer F, Rodicio JL.(2000)** Policies concerning the use of kidneys from donors infected with hepatitis C virus. *Nephrol Dial Transplant.* ;15 Suppl 8:71-3

**Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. (2008)** Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.*Gastroenterology.*; 134(2):416-23.

**Muñoz AE, Levi D, Podestá A, Gorín JM, González J, Bartellini MA, Munne MS, Cabanne A, Flichman D, Terg R.(2000)** Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial. [Gut.](#); 46(3):427-31.

**Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, Williams AE, Nass CC, Ownby HE, Schreiber GB, Kong F, Neal KR, Nemo GJ(2000)** Risk Factors for Hepatitis C Virus Infection in United States Blood Donors *Hepatology.* 2000 Mar; 31(3):756-62.

**National Institutes of Health Consensus Development Conference Panel statement (1997)** Management of hepatitis C *Hepatology.* ;26(3 Suppl 1):2S-10S.

**National Institutes of Health Consensus Development Conference Statement(2002)** Management of hepatitis C , *Hepatology*; 36(5 Suppl 1): S3-20

**Natov SN, Lau JY, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS, Pereira BJ.( 1998)** Serologic and virologic profiles of hepatitis C infection in renal transplant candidates. *New England Organ Bank Hepatitis C Study Group. [Am J Kidney Dis.](#)*; 31(6):920-7.

**Natov SN, Lau JY, Ruthazer R, Schmid CH, Levey AS, Pereira BJ. (1999)**,Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. *The New England Organ Bank Hepatitis C Study Group.[Kidney Int](#)* ;56(2):700-6.

**Natov SN, Pereira BJ.( 1996)** . Hepatitis C in dialysis patients. *Adv Ren Replace Ther.* ;3(4):275-83.

**Natov SN, Pereira BJ.( 2003)**.Chapter 32-Liver Disease Among Renal Transplant Recipients in *Peter J.Morris Kidney Transplantation: Principles and Practice 5<sup>th</sup> ed.* Copyright © [2003 Saunders](#),pp518.

**Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, Elewaut A, Desmet V, Leroux-Roels G, Quinaux E, Depla E, Dincq S, Vander Stichele C, Maertens G, Hulstaert F.( 2003)** A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. *[Hepatology.](#)* ;38(5):1289-96.

**Ning Q, Brown D, Parodo J, Cattral M, Gorczyński R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G.(1998)** Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. *[J Immunol.](#)*; 160(7):3487-93.

- Noto, H, Raskin, P(2006)** Hepatitis C infection and diabetes. [J Diabetes Complications.](#); 20(2):113-20.
- Ogata K, Koga T, Yagawa K.( 1994)** Interferon-related bronchiolitis obliterans organizing pneumonia. [Chest.](#); 106(2):612-3.
- Okuda K, Hayashi H, Yokozeki K, Irie Y(1996)** Destruction of hepatitis C virus particles by hemodialysis. *Lancet.*; 347(9005):909-10.
- Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M.( 2006)** De novo glomerulonephritis in renal allografts with hepatitis C virus infection [Transplant Proc.](#);38(2):492-5.
- Ozdemir BH, Ozdemir FN, Sezer S, Haberal M. (2007)** Influence of pretransplant IFN-alpha therapy on interstitial fibrosis in renal allografts with hepatitis C virus infection.[Ren Fail.](#) 2007;29(5):615-22.
- Pawlotsky JM, Bouvier M, Fromont P, Deforges L, Duval J, Dhumeaux D, Bierling P. (1995)** Hepatitis C virus infection and autoimmune thrombocytopenic purpura.*J Hepatol.*;23(6):635-9.
- Pereira BJ, Levey AS(1997)** . Hepatitis C virus infection in dialysis and renal transplantation.*Kidney Int.* ;51(4):981-99.
- Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS.( 1998)** Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. *Kidney Int.*;53(5):1374-81.

**Periera BJ, Wright TL, Schmid CH, Levey AS(1995)** The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. *Transplantation.*;60(8):799-805.

**Peters, M (1989)** Mechanisms of action of interferons. *Semin Liver Dis.*;9(4):235-9.

**Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P.(2001)** Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. *J Hepatol.* ;35(2):279-83.

**Pilli M, Penna A, Zerbini A, Vescovi P, Manfredi M, Negro F, Carrozzo M, Mori C, Giuberti T, Ferrari C, Missale G.(2002)** Oral lichen planus pathogenesis:A role for the HCV-specific cellular immune response. *Hepatology.*;36(6):1446-52.

**Pirovino M, Linder R, Boss C, Köchli HP, Mahler F. (1988)** Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. *Klin Wochenschr.* 1988 Apr 1;66(7):298-302.

**Planas R, Ballesté B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, Santos J, Coll S, Morillas RM, Solà R.( 2004)**Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. *J Hepatol.* ;40(5):823-30.

**Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, Sullivan S,Blatt LM, Faris-Young S.(2007)** Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. *Hepatology*;45(3):569-78.

**Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, Carithers RL, McHutchison JG, Olek E, Debruin MF(2003)** A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. [Hepatology](#). ;37(6):1368-74.

**Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA.(2007)** Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. [Hepatology](#). ;46(2):324-9.

**Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, Serfaty L, Bedossa P, Bréchet C.(2004)** Reversibility of hepatitis C virus-related cirrhosis. [Hum Pathol](#).;35(1):107-12.

**Ramos-Casals M, Loustaud-Ratti V, De Vita S, Zeher M, Bosch JA, Toussirot E, Medina F, Rosas J, Anaya JM, Font J; SS-HCV Study Group (2005)** Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. *Medicine (Baltimore)*.;84(2):81-9.

**Ramos-Casals M, Mañá J, Nardi N, Brito-Zerón P, Xaubet A, Sánchez-Tapias JM, Cervera R, Font J; HISPAMEC Study Group(2005)** Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. [Medicine \(Baltimore\)](#). ;84(2):69-80.

**Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E, Petridou P, Vrettou H, Vagionas G, Galaktidou G, et al. (1995)** Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients.[Nephrol Dial Transplant](#). ;10(10):1834-7.

**Rodriguez-Torres M, Lawitz E, Godofsky E, et al.(2005):** Valopicitabine (nm283) alone and in combination with peg-interferon in patients with genotype 1 chronic hepatitis C: preliminary results from an ongoing

phase II, multicenter study [abstract]. *Gastroenterology*;128(suppl 2):A-695-A-696.

**Rostaing L, Chatelut E, Payen JL, Izopet J, Thalamas C, Ton-That H, Pascal JP, Durand D, Canal P.( 1998)** Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. [J Am Soc Nephrol.](#); 9(12):2344-8.

**Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. (1996)** Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. [Nephron.](#); 74(3):512-6.

**Roth D, Cirocco R, Zucker K, Ruiz P, Viciano A, Burke G, Carreno M, Esquenazi V, Miller J.(1995)** De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. [Transplantation.](#); 59(12):1676-82.

**Roth D, Zucker K, Cirocco R, Burke G, Ciancio G, Esquenazi V, Swanson SJ 3rd, Miller J.(1996)** A prospective study of hepatitis C virus infection in renal allograft recipients. [Transplantation.](#);61(6):886-9

**Russo MW, Ghalib R, Sigal S, Joshi V.( 2006)** Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. [Nephrol Dial Transplant.](#); 21(2):437-43.

**Saadoun D, Asselah T, Resche-Rigon M, Charlotte F, Bedossa P, Valla D, Piette JC, Marcellin P, Cacoub P. (2006)** Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. [Hepatology.](#);43(6):1337-45.

**Sabry AA, Sobh MA, Sheaashaa HA, Kudesia G, Wild G, Fox S, Wagner BE, Irving WL, Grabowska A, El-Nahas AM. (2002)** Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. [Nephrol Dial Transplant.](#) ;17(11):1924-30.

[Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S.](#)( 2007) SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.[Gastroenterology.](#); 132(4):1270-8.

**Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, Cavalletto L, Schvarcz R, Ideo G, Alberti A.(1997),**Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.[J Hepatol.](#);26(5):961-6.

**Schott E, Witt H, Neumann K, Taube S, Oh DY, Schreier E, Vierich S, Puhl G, Bergk A, Halangk J, Weich V, Wiedenmann B, Berg T.( 2007)** A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. [J Hepatol.](#); 47(2):203-11.

**Shaker JL, Moore BP, Whyte MP.( 1999)** Hyperparathyroidism and increased serum IGF-binding protein-2 levels in hepatitis C-associated osteosclerosis. [J Clin Endocrinol Metab.](#); 84(1): 384-5.

**Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, Conjeevaram HS, Sallie R, Di Bisceglie AM. (1995)** Volunteer blood donors with antibody to hepatitis C virus: clinical,

biochemical, virologic, and histologic features. The Hepatitis C Study Group. [Ann Intern Med.](#); 123(5):330-7.

**Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.(2006)** Chronic hepatitis C virus infection in renal transplant: treatment and outcome. [Clin Transplant.](#); 20(6):677-83.

**Shepard CW, Finelli L, Alter M (2005)** Global epidemiology of hepatitis C virus infection [Lancet Infect Dis.](#) ;5(9):558-67.

**Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD. (2004)** Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. [Transplantation.](#) ;77(12):1894-6.

**Soper NJ, Rikkers LF.( 1982)** Effect of operations for variceal hemorrhage on hypersplenism. *Am J Surg.* ;144(6):700-3.

**Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases (2004)** Diagnosis, management, and treatment of hepatitis C. *Hepatology.*; 39(4):1147-71.

**Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, Omata M.( 1994)**A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. *Hepatology.* ; 20(3):558-64.

**Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing Ho Y, Neng Lai K, Mao Chan T,(2003):** Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha- 2b and ribavirin. *J Hepatol* 39: 875–878.

**Terrault NA, Adey DB (2007)** The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. [Clin J Am Soc Nephrol.](#);2(3):563-75.

**Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, Kullmann F, Ramadori G, Arnold R, Weidenbach H, Musch E, Junge U, Wiedmann KH, Herrmann E, Zankel M, Zeuzem S(2003)** Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. [J Hepatol.](#) ;39(4):606-13.

**The French METAVIR Cooperative Study Group,(1994)** Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology.* ;20(1 Pt 1):15-20.

**The National Institutes of Health Consensus Development Conference. Management of hepatitis C(1997)** *Hepatology.* ;26(3 Suppl 1):2S-10S.

**Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ.(1998)** A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. [Int J Epidemiol.](#); 27(1):108-17.

**Thuluvath PJ, Maheshwari A, Mehdi J, Fairbanks KD, Wu LL, Gelrud LG, Ryan MJ, Anania FA, Lobis IF, Black M(2004)** Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. [Gut.](#); 53(1):130-5.

**Tosti A, Misciali C, Bardazzi F, Fanti PA, Varotti C.(1992)** Telogen effluvium due to recombinant interferon alpha-2b. [Dermatology.](#); 184(2):124-5.

**Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyake S, Sakai T, Akiba T, Marumo F, Sato C. (1998)** Interferon therapy for chronic hepatitis C in

hemodialysis patients: increased serum levels of interferon. *Nephron*; 80(1):51-6.

**Ucmak H, Kokoglu OF, Hosoglu S, Dogan E, Sayarlioglu H, Kuzhan N, Isik IO.(2008)** Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. [Ren Fail.](#); 30(2):227-32.

**Umlauft F, Gruenewald K, Weiss G, Kessler H, Urbanek M, Haun M, Santner B, Koenig P, Keeffe EB.( 1997)** Patterns of hepatitis C viremia in patients receiving hemodialysis. [Am J Gastroenterol.](#); 92(1):73-8.

**Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, Abrignani S, Lin YL, Houghton M, O'Hagan DT.(2006)** Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. *J Gen Virol.*; 87(Pt 8):2253-62.

**Von Herbay A, Stahl W, Niederau C, Sies H.( 1997)** Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study.[Free Radic Res.](#); 27(6):599-605.

**Weinstein T, Tur-Kaspa R, Chagnac A, Korzets A, Ori Y, Zevin D, Herman M, Gafter U.( 2001).**Hepatitis C infection in dialysis patients in Israel. *Isr Med Assoc J.*; 3(3):174-7.

**Widell A, Månsson S, Persson NH, Thysell H, Hermodsson S, Blohme I.(1995)** Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. [Transplantation.](#) 15;60(7):642-7

**Zauli D, Ghetti S, Grassi A, Descovich C, Cassani F, Ballardini G, Muratori L, Bianchi FB. (1997)** Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. *Hepatology*.; 25(5):1105-7.

**Zein CO, Levy C, Basu A, Zein NN. (2005)** Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. [Am J Gastroenterol](#).; 100(1):48-55.

**Zein NN (2000)** Clinical significance of hepatitis C virus genotypes *Clin Microbiol Rev*; 13(2):223-35.

**Zekry A, Gleeson M, Guney S, McCaughan GW.(2004)**, A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. [Liver Transpl](#). ;10(1):52-7.

**Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, Bain VG, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG.(2008)** Sustained virologic response rates with albinterferon alfa-2B plus ribavirin treatment in IFN-naive chronic hepatitis C genotype 1 patients. [Hepatology](#).; 48(2):407-17.

**Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, Feinstone SM.( 2007)** Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. [Proc Natl Acad Sci U S A](#).; 104(20):8449-54.